IGC Pharma, Inc. (NYSEAMERICAN:IGC) Short Interest Update

IGC Pharma, Inc. (NYSEAMERICAN:IGC) was the target of a large increase in short interest during the month of December. As of December 15th, there was short interest totaling 428,376 shares, an increase of 46.3% from the November 30th total of 292,751 shares. Currently, 0.6% of the company’s shares are short sold. Based on an average daily volume of 707,283 shares, the short-interest ratio is presently 0.6 days. Based on an average daily volume of 707,283 shares, the short-interest ratio is presently 0.6 days. Currently, 0.6% of the company’s shares are short sold.

IGC Pharma Trading Down 5.0%

IGC stock traded down $0.01 during trading on Tuesday, hitting $0.28. The company had a trading volume of 728,506 shares, compared to its average volume of 1,135,443. IGC Pharma has a one year low of $0.25 and a one year high of $0.50. The stock has a 50-day moving average price of $0.34. The firm has a market cap of $26.24 million, a PE ratio of -4.04 and a beta of 0.24. The company has a debt-to-equity ratio of 0.02, a quick ratio of 0.89 and a current ratio of 1.32.

IGC Pharma (NYSEAMERICAN:IGC) last issued its quarterly earnings results on Friday, November 14th. The company reported ($0.02) EPS for the quarter. IGC Pharma had a negative net margin of 583.91% and a negative return on equity of 96.54%. The firm had revenue of $0.19 million for the quarter.

About IGC Pharma

IGC Pharma, Inc, a clinical stage biotechnology company, engages in developing cannabinoid-based formulations for treating diseases and conditions, including Alzheimer’s disease, dysmenorrhea, premenstrual syndrome, and chronic pain. The company has two investigational drug assets targeting Alzheimer’s disease comprising IGC-AD1, which is in a Phase 2B clinical trial as a treatment for agitation in dementia due to Alzheimer’s; and TGR-63 that is in pre-clinical development. It also markets Holief, a wellness brand that targets women experiencing premenstrual syndrome and menstrual cramps.